Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Revenue: 2010-2025

Historic Revenue for Vanda Pharmaceuticals (VNDA) over the last 16 years, with Sep 2025 value amounting to $56.3 million.

  • Vanda Pharmaceuticals' Revenue rose 18.06% to $56.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $212.1 million, marking a year-over-year increase of 11.12%. This contributed to the annual value of $198.8 million for FY2024, which is 3.18% up from last year.
  • Vanda Pharmaceuticals' Revenue amounted to $56.3 million in Q3 2025, which was up 6.97% from $52.6 million recorded in Q2 2025.
  • Vanda Pharmaceuticals' Revenue's 5-year high stood at $70.1 million during Q3 2021, with a 5-year trough of $38.8 million in Q3 2023.
  • For the 3-year period, Vanda Pharmaceuticals' Revenue averaged around $50.0 million, with its median value being $50.0 million (2025).
  • In the last 5 years, Vanda Pharmaceuticals' Revenue tumbled by 40.58% in 2023 and then rose by 22.76% in 2024.
  • Over the past 5 years, Vanda Pharmaceuticals' Revenue (Quarterly) stood at $68.0 million in 2021, then fell by 5.20% to $64.5 million in 2022, then decreased by 29.79% to $45.3 million in 2023, then increased by 17.48% to $53.2 million in 2024, then rose by 18.06% to $56.3 million in 2025.
  • Its Revenue stands at $56.3 million for Q3 2025, versus $52.6 million for Q2 2025 and $50.0 million for Q1 2025.